UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 74

Sortiert nach

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Frontiers in immunology, 2020-08, Vol.11, p.1771-1771

2020

Volltextzugriff (PDF)

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

The Journal of immunology (1950), 2005-10, Vol.175 (8), p.5370-5378

2005

Volltextzugriff (PDF)

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

Oncotarget, 2014-05, Vol.5 (10), p.3362-3374

2014

Volltextzugriff (PDF)

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2

Bioorganic & medicinal chemistry letters, 2010-12, Vol.20 (24), p.7473-7478

2010

Volltextzugriff (PDF)

Identification of a regulatory autophosphorylation site in the serine–threonine kinase RIP2

Cellular signalling, 2006-12, Vol.18 (12), p.2223-2229

2006

Volltextzugriff (PDF)

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist

Bioorganic & medicinal chemistry letters, 2011-03, Vol.21 (5), p.1442-1446

2011

Volltextzugriff (PDF)

Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2

Biochemical and biophysical research communications, 2009-09, Vol.387 (2), p.251-255

2009

Volltextzugriff (PDF)

Participation of Rip2 in Lipopolysaccharide Signaling Is Independent of Its Kinase Activity

The Journal of biological chemistry, 2005-04, Vol.280 (16), p.16278-16283

2005

Volltextzugriff (PDF)

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist

ACS medicinal chemistry letters, 2011-06, Vol.2 (6), p.450-454

2011

Volltextzugriff (PDF)

Functional Isolation and Characterization of Human Hematopoietic Stem Cells

Science (American Association for the Advancement of Science), 1995-01, Vol.267 (5194), p.104-108

1995

Volltextzugriff (PDF)

Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1632-1632

2021

Volltextzugriff (PDF)

Prediction and Allocation of EDP Based on Gray Model and Fuzzy Comprehensive Evaluation

Mathematical problems in engineering, 2021, Vol.2021, p.1-8

2021

Volltextzugriff (PDF)

Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

Molecular cancer therapeutics, 2021-10, Vol.20 (10), p.1916-1925

2021

Volltextzugriff (PDF)

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma

Science translational medicine, 2010-09, Vol.2 (51), p.51ra70

2010

Volltextzugriff (PDF)

CD38 Protects Tumor Cells from NK Lysis

Blood, 2015-12, Vol.126 (23), p.5389-5389

2015

Volltextzugriff (PDF)

A new chiral diphosphine ligand and its asymmetric induction in catalytic hydroformylation of olefins

Catalysis today, 2000-12, Vol.63 (2), p.531-536

2000

Volltextzugriff (PDF)

Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.2966-2966

2019

Volltextzugriff (PDF)

Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model

Bioorganic & medicinal chemistry letters, 2020-12, Vol.30 (23), p.127625-127625, Article 127625

2020

Volltextzugriff (PDF)

Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened

ChemMedChem, 2013-08, Vol.8 (8), p.1261-1265

2013

Volltextzugriff (PDF)

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene

Blood, 2014-09, Vol.124 (11), p.1777-1789

2014

Volltextzugriff (PDF)

Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

ACS medicinal chemistry letters, 2023-01, Vol.14 (1), p.116-122

2023

Volltextzugriff (PDF)

Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors

ACS medicinal chemistry letters, 2023-01, Vol.14 (1), p.5-10

2023

Volltextzugriff (PDF)

Abstract B26: Immunomodulatory activity of Isatuximab

Cancer immunology research, 2017-03, Vol.5 (3_Supplement), p.B26-B26

2017

Volltextzugriff (PDF)

Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors – Lead optimization – Part III

Bioorganic & medicinal chemistry letters, 2019-02, Vol.29 (3), p.491-495

2019

Volltextzugriff (PDF)

Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach

ACS medicinal chemistry letters, 2023-03, Vol.14 (3), p.312-318

2023

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(72)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)
Japanisch
(10)

Erscheinungsjahr

n.n

Thema

Science & Technology
(49)
Life Sciences & Biomedicine
(33)
Humans
(23)
Physical Sciences
(19)
Animals
(15)
Chemistry
(15)
Mice
(15)
Chemistry, Organic
(14)
Chemistry, Medicinal
(11)
Pharmacology & Pharmacy
(11)
Biological And Medical Sciences
(9)
Biochemistry & Molecular Biology
(8)
Antagonist
(6)
Cell Line, Tumor
(6)
Molecular Sequence Data
(6)
Structure-Activity Relationship
(6)
Cell Biology
(5)
Cell Line
(5)
Female
(5)
Fundamental And Applied Biological Sciences. Psychology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

Discovery and Pharmacological Characterization of a Novel Rodent-Active CCR2 Antagonist, INCB3344

Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2

Identification of a regulatory autophosphorylation site in the serine–threonine kinase RIP2

Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist

Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2

Participation of Rip2 in Lipopolysaccharide Signaling Is Independent of Its Kinase Activity

Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist

Functional Isolation and Characterization of Human Hematopoietic Stem Cells

Abstract 1632: Antibody mediated crosslinking of CD38 triggers costimulatory signaling and promotes T cell effector function

Prediction and Allocation of EDP Based on Gray Model and Fuzzy Comprehensive Evaluation

Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma

CD38 Protects Tumor Cells from NK Lysis

A new chiral diphosphine ligand and its asymmetric induction in catalytic hydroformylation of olefins

Abstract 2966: Isatuximab-induced multiple myeloma cell killing through effector functions is dependent on CD38 expression and complement inhibitors

Discovery of SARxxxx92, a pan-PIM kinase inhibitor, efficacious in a KG1 tumor model

Discovery of NVP-LEQ506, a Second-Generation Inhibitor of Smoothened

PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene

Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors

Abstract B26: Immunomodulatory activity of Isatuximab

Discovery of N-substituted 7-azaindoles as Pan-PIM kinases inhibitors – Lead optimization – Part III

Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach

Suchergebnisse filtern